Endophytic Fungi: Key Insights, Emerging Prospects, and Challenges in Natural Product Drug Discovery.

Plant-associated endophytes define an important symbiotic association in nature and are established bio-reservoirs of plant-derived natural products. Endophytes colonize the internal tissues of a plant without causing any disease symptoms or apparent changes. Recently, there has been a growing interest in endophytes because of their beneficial effects on the production of novel metabolites of pharmacological significance. Studies have highlighted the socio-economic implications of endophytic fungi in agriculture, medicine, and the environment, with considerable success. Endophytic fungi-mediated biosynthesis of well-known metabolites includes taxol from Taxomyces andreanae, azadirachtin A and B from Eupenicillium parvum, vincristine from Fusarium oxysporum, and quinine from Phomopsis sp. The discovery of the billion-dollar anticancer drug taxol was a landmark in endophyte biology/research and established new paradigms for the metabolic potential of plant-associated endophytes. In addition, endophytic fungi have emerged as potential prolific producers of antimicrobials, antiseptics, and antibiotics of plant origin. Although extensively studied as a "production platform" of novel pharmacological metabolites, the molecular mechanisms of plant-endophyte dynamics remain less understood/explored for their efficient utilization in drug discovery. The emerging trends in endophytic fungi-mediated biosynthesis of novel bioactive metabolites, success stories of key pharmacological metabolites, strategies to overcome the existing challenges in endophyte biology, and future direction in endophytic fungi-based drug discovery forms the underlying theme of this article.

1. Introduction

Endophytes represent biological reservoirs of novel natural products, opening new avenues in the frontiers of drug discovery. Plant-associated microorganisms that colonize the internal tissues of all plant species are gaining momentum as key targets for bio-prospection in the search for novel chemical entities [1,2]. The discovery of the acclaimed anticancer drug paclitaxel accelerated research on endophytic biology and yielded prospective “drug candidates” with antimicrobial, immunosuppressant, antioxidant, and anti-neurodegenerative functions [1,2,3]. Currently, the impact of natural products in clinical applications cannot be underestimated [4], with the pharmaceutical sector adopting high-throughput approaches to screen plant secondary metabolites as potential lead molecules. According to a study by Newman and Cragg [5], among the 1562 drugs approved by the FDA, 141 comprised botanical drugs, 64,320 drugs were derivatives of natural products, while 61 drugs were synthesized based on natural pharmacophore [5].

With the emerging threat of drug-resistant microbes and antimicrobial resistance (AMR), it has become essential to discover novel antimicrobials to counter AMR. However, the low pace of discovery and indiscriminate use of the existing antibiotics have further necessitated the exploration of novel antimicrobial entities to compensate for the drying drug pipeline [2,6,7,8]. The rich yet less-explored diversity of endophytic entities and their considerable potential to impact the pharmaceutical industry have facilitated the discovery of secondary metabolites of therapeutic significance (Figure 1. Bio-prospection of endophytes and discovery of novel, high-value metabolites of commercial significance, including hinnuliquinone, a potent inhibitor of the HIV-1 protease [9]; cytonic acids A and B, human cytomegalovirus protease inhibitors [10]; pestacin and isopestacin, antioxidants [11]; paclitaxel, antineoplastic agents [12]; and lariatins A and B, anti-HIV agents [13]. The discovery and commercial production of paclitaxel from different endophytic species revolutionized the pharmaceutical industry (with FDA approval in 1992), and the diterpene natural product garnered commercial sales of over $3 billion in 2004 [14].

Figure 1

Bio-prospection of endophytes and discovery of novel, high-value metabolites of commercial significance.

With increasing research on the discovery of natural products from biological species, endophytes are increasingly being explored as production platforms for bioactive metabolites with diverse chemical structures. The discovery of taxol from the endophytic fungus Taxomyces andreanae in 1993 [15], and subsequently from other endophytic species, led to renewed research on pharmacological metabolites from endophytic sources. Furthermore, studies have established that endophytes mimic host metabolism and can produce, induce, and modify the metabolic chemical entities within hosts [16,17]. Endophytic fungi are one of the most promising candidates for endophyte-mediated natural product discovery. Diverse bioactive metabolites produced by endophytic fungi have demonstrated socio-economic importance and found applications in agriculture (as biofertilizers/biostimulants) and the environment (bioremediation), as biofuels/biocatalysts, in addition to their pharmacological attributes. Table 1 provides an overview of endophytic fungi in the environment, including multifaceted applications, key examples, and translational outcomes. As useful metabolites with multifaceted environmental implications are increasingly being discovered, different strains of endophytic fungi are being investigated and the associated limitations are being addressed for maximum use/multifaceted applications.

Table 1

Endophytic fungi in environment: significant multi-faceted applications, key examples, and translational outcomes.

Biological Application	Endophytic Fungi	Plant Species	Outcome	Reference
Plant growth promotion and agriculture
Plant growth promotion (PGP)	Penicillium sp. 21	Camellia sinensis	Mineral-solubilizing function (Ca3(PO4)2 and rock phosphate)	[18,19]
	Penicillium sp. 2
	Aspergillus sp. MNF
	Trichoderma gamsii (NFCCI 2177)	Lens esculenta	Solubilization of Tricalcium phosphate	[20]
	Trichoderma peudokoningi	Solanum lycopersicum	Siderophore production, HCN and ammonia production	[21]
	Chaetomium globosum
	Fusarium oxysporum
	Ophiosphaerella sp.	Triticum aestivum	PGP activities	[22]
	Cochliobolus sp.
	Cladosporium sphaerospermum	Glycine max	Solubilize calcium phosphate	[23]
	Fusarium tricinctum RSF-4L	S. nigrum	Production of phytohormones (gibberellins)	[24]
	Alternaria alternata RSF-6L
	Endophytic fungi	Hordeum murinum subsp. murinum	IAA production, PGP activitiesPlant yield increase	[25]
Biofertilizers/biostimulants for crops	Aspergillus sp.	S. officinarum	Phosphorous solubilization	[26]
	Penicillium sp. 1
	Penicillium sp. 2
	Cochliobolus sp.	T. aestivum	Phosphorous solubilization	[26]
	Curvularia sp.
	Fusarium equiseti	Pisum sativum	Phosphorous solubilization	[27]
	Coniothyrium aleuritis isolate 42	Lycopersicon esculentum	Plant biomass increase, fruit yield	[28]
	Pichia guilliermondii isolate F15
	Fusarium oxysporum strain NSF2
	Fusarium proliferatum strain AF04
	Aspergillus nidulans strain FH5
	Trichoderma spirale strain YIMPH30310
Biocontrol function	Fusarium verticillioides	Zea mays	Restrict Ustilago maydis growth	[29]
	Penicillium sp.	Cucumis sativus	Biocontrol of Fusarium oxysporum f. sp. cucumerinum	[30]
	Guignardia mangiferae
	Hypocrea sp.
	Neurospora sp.
	Eupenicillium javanicum
	Lasiodiplodia theobromae
Biotic/abiotic stress tolerance	Piriformospora indica	Hordeum vulgare	Drought stress tolerance	[31]
	P. indica	Brassica rapa	Drought stress tolerance	[32]
	P. indica	H. vulgare	Biotic/abiotic stress tolerance	[25]
Bioremediation	Mucor sp. MHR-7	Brassica campestris	Metal toxicity reduction	[33]
	Rhizopus sp. CUC23	Lactuca sativa	Chromium detoxification	[34]
	A. fumigatus ML43
	Penicillum radicum PL17
	Endophytic fungi	Agrostis stolonifera	Bioremediation of lead	[35]
	Neotyphodium coenophialum	Festuca arundinacea, Festuca pratensis	Bioaugmentation, total petroleum hydrocarbons (TPH) and polycyclic aromatic hydrocarbons (PAHs) removal from the soil	[36]
	N. uncinatum
	Verticillium sp. Xylaria sp.	Plants from Ecuadorian Amazon	Degradation of Petroleum hydrocarbon	[37]
	Endophytic fungi	-	Bioremediation of synthetic plastic polymers	[38]
	Curvularia sp.	Mangrove sp.	Heavy metal biosorption	[39]
	Neusartorya sp.
	Bjerkandera adusta SWUSI4	Sinosenecio oldhamianus	Detoxification of triphenylmethane dyes	[40]
	Lasiodiplodia theobromae	Boswellia ovalifoliolata	Heavy metal tolerance	[41]
	Lindgomycetaceae P87 Aspergillus sp. A31	Aeschynomene fluminensis	Heavy metal resistance, bioremediation	[42]
Bioactive metabolites for industrial and pharmacological applications
Paclitaxel	Taxomyces andreanae T. brevifolia	Pacific yew	Anticancer	[15]
Azadirachtin A and B	Eupenicillium parvum	Azadirachta indica	Insecticidal	[43]
Subglutinol A	Fusarium subglutinans	Tripterygium wilfordii	Immuno-suppressant	[44]
Isopestacin	Pestalotiopsis microspora	Terminalia morobensis	Antifungal, Antioxidant	[11]
Podophyllotoxin	Trametes hirsuta	Podophyllum hexandrum	Antiviral, Radio-protective	[45]
Forskolin	Rhizoctonia bataticola	Coleus forskohlii	Anti-HIV, Antitumor	[46]
Sanguinarine	Fusarium proliferatum	Macleaya cordata	Antihelmintic	[47]
Digoxin	Alternaria sp.	Digitalis lanata	Cardiotonic	[48]
Quinine	Phomopsis sp.	Cinchona ledgeriana	Antimalarial	[49]
Capsaicin	Alternaria alternata	Capsicum annuum	Cardio-protective	[50]

Although plant-associated endophytes serve as “biosynthetic platforms” of pharmaceutically important secondary metabolites, challenges exist in terms of the limited knowledge of endophyte biology and decreased production of secondary metabolites due to repeated sub-culturing of endophytic strains, projecting a need to adopt a more integrated and systematic approach towards the exploitation of endophytes in drug discovery and research. In this direction, a comprehensive insight into plant–endophyte associations and their dynamics is necessary to understand how and why endophytes biosynthesize secondary metabolites [51]. Another prospective strategy is to develop strain improvement methods using genetic engineering, optimization of culture conditions/media for cultivation, and co-culturing of different endophytic strains. Recent advances in high-throughput technologies and the “genomic revolution” have contributed considerably to natural product research and the discovery of biosynthetic gene clusters (BGCs) [52,53]. Genetic engineering of endophytes is still in its infancy and is often regarded as a progenitor of system biology and functional genomics strategies [54] with the potential for long-term translational success. Endophytes mimic their host plant in independent biosynthesis of secondary metabolites, thus acting as a prospective platform for genetic manipulation [14]. Studies have suggested the inclusion of metabolic pathways and genes in endophytes via genetic recombination between plant hosts and endophytes [55,56]. In addition, horizontal gene transfer, an evolutionary mechanism, has been suggested as an adaptive mechanism for endophytes, and it confers novel traits to the associated microbes [56].

Moreover, approaches in metagenomics, whole-genome sequencing, and omics biology have further enabled access to the less explored natural product reservoirs of plant-associated endophytes. The existing and emerging trends in endophytic fungi-mediated biosynthesis of novel bioactive metabolites, success stories of key pharmacological metabolites, strategies to overcome the existing/forthcoming challenges in endophytic biology, and future directions/outcomes in endophytic fungi-based drug discovery form the underlying theme of this article.

2. Bioactive Metabolites from Endophytic Fungi as Novel Drug Candidates

Plants possessing pharmacological properties and bioactive metabolites are used to treat ailments in modern healthcare [57]. The small molecule drugs approved from 1981–2014 comprise more than 51% of natural products [58]. However, the indiscriminate use of natural products has threatened natural resources, specifically plant species, and led to a shortage of novel bioactive metabolites. Thus, it is imperative to explore other eco-friendly alternatives to produce high-value phytochemicals and plant-associated endophytes, which are emerging as a highly attractive source. The emerging significance of secondary metabolites from endophytes is largely attributed to their multifaceted applications, ranging from pharmaceutical drugs and immune suppressants to agriculture and industrial uses. The majority (38%) of the bioactive metabolites, including antibiotics, were isolated from fungi out of 22,500 microbe-derived compounds [59]. Recently, the slow pace of antibiotic discovery and rising AMR have hampered the drug discovery process.

Plant-associated endophytes comprise bacterial and fungal species that colonize internal plant tissues and complete their partial or entire life cycle inside the host plant. Showing universal occurrence and inhabiting almost all vascular plant species, endophytes demonstrate multifaceted advantages to the host plant by promoting growth, conferring tolerance to biotic/abiotic stresses [29], and biosynthesizing bioactive secondary metabolites [43]. Recent investigations into the ecological perspective of secondary metabolite production include protection against pathogens [60,61], mitigation of abiotic stress in plants [62], and herbivore deterrence [63]. An investigation into the natural product chemistry of endophytes highlighted the remarkable potential of endophytes in the production of phytochemicals and emerging platforms for the fabrication of novel antimicrobial entities [64]. Table 2 presents current state of knowledge on the production of endophytic fungi-mediated secondary metabolites and their pharmacological significance. It is imperative to understand plant–endophyte dynamics and how endophytes are a key source of phytochemicals. Endophytes influence their host and induce favorable responses in different ways, including elicitation of novel phytochemicals, plant growth augmentation, and conferring stress (abiotic/biotic) tolerance to the host plant [64].

Table 2

Production of endophytic fungi-mediated secondary metabolites and their pharmacological significance.

Endophytic Fungi	Fungi and Fungus-Like Taxa	Plant Association	Bioactivity	Secondary Metabolite	Class of Compound	Active Concentration	Pathogen(s)	Reference
Pestalotiopsis foedan	Coelomycetes	Bruguiera sexangula	Antifungal	(3R,4R,6R,7S)-7-hydroxyl-3,7-dimethyl-oxabicyclo [3.3.1] nonan-2-one	Monoterpene lactone	3.1 µg/mL (MIC)	Botrytis cinerea Phytophthora nicotianae	[65]
				(3R,4R)-3-(7-methylcyclohexenyl)-propanoic acid		6.3 µg/mL		[66]
Pestalotiopsis sp. DO14	Coelomycetes	Dendrobium officinale	Antifungal,Cytotoxic	(4S,6S)-6-[(1S,2R)-1,2-dihydroxybutyl]-4-hydroxy-4-methoxytetrahydro-2H-pyran-2-one	Monoterpenoid	≤25 µg/mL (MIC)	Candida albicans Cryptococcus neoformans Trichophyton rubrum Aspergillus fumigatus	[67]
				(6S,2E)-6-hydroxy-3-methoxy-5-oxodec-2-enoic acid
Diaporthe maritima	Coelomycetes	Picea sp.	Antifungal	Phomopsolide A	Dihydropyrones	25 µM (MIC)	Microbotryum violaceum	[68]
				Phomopsolide B		250 µM
				Phomopsolide C		250 µM
Scleroderma UFSM Sc1	Basidiomycetes	Eucalyptus grandis	Antifungal,Insecticidal	Sclerodol A	Lanostane-type triterpenes	50 µg/mL (MIC)50 µg/mL12.5 µg/mL25 µg/mL	C. albicans C. tropicalis C. crusei C. parapsilosis	[69]
				Sclerodol B		25 µg/mL25 µg/mL6.25 µg/mL12.5 µg/mL
Fusarium fujikuroi (WF5)	Hyphomycetes	Eleusine coracana	Antifungal	5-hydroxy 2(3H)-benzofuranone	Furanone	31.25 µg/mL (MIC)	F. graminearum	[70]
				Harpagoside	Iridoide glycoside	31.25 µg/mL
TrichodermakoningiopsisYIM PH30002	Hyphomycetes	Panax notoginseng	Antifungal	Koningiopisin C	Polyketides	32 µg/mL (MIC)64 µg/mL32 µg/mL16 µg/mL	F. oxysporum A. panax F. solani P. cucumerina	[71]
Trichoderma brevicompactum 0248	Hyphomycetes	Allium sativum	Antifungal	Trichodermin	Sesquiterpene	EC50 of 0.25 µg/mL2.02 µg/mL25.60 µg/mL	R. solani B. cinerea C. lindemuthianum	[72]
Aspergillus sp.	Hyphomycetes	Gloriosa superba	Antimicrobial,Cytotoxic	6-methyl-1,2,3-trihydroxy-7,8-cyclohepta-9,12-diene-11-one-5,6,7,8-tetralene-7-acetamide (KL-4)	Tetralene derivative	25 µg/mL (MIC)12.5 µg/mL50 µg/mL	S. cerevisiae C. albicans C. gastricus	[73]
Penicillium sp. R22	Hyphomycetes	Nerium indicum	Antifungal	3-O-methylviridicatin	Isoquinolone alkaloid	31.2 µg/mL (MIC)	A. brassicae B. cinerea V. mali	[74]
				Viridicatol		31.2 µg/mL	A. brassicae A. alternata B. cinerea
				5-hydroxy-8-methoxy-4-phenylisoquinolin-1(2H)-one		31.2 µg/mL	A. brassicae A. alternata V. mali
Trichoderma sp. 09	Hyphomycetes	Myoporum bontioides	Antifungal	Dichlorodiaportin	Isocoumarin	6.25–150 µg/mL(MIC)	C. musae Rhizoctonia solani	[75]
				Dichlorodiaportinolide
Fusarium chlamydosporium	Hyphomycetes	Anvillea garcinii	Antimicrobial,Cytotoxic	Fusarithioamide A	Benzamide derivative	3.1 μg mL−1 (MIC)4.4 μg mL−16.9 μg mL−1	B. cereus S. aureus E. coli	[76]
Curvularia sp., strain M12	Hyphomycetes	Murraya koenigii	Antifungal	Murranofuran A	Dihydrofurans	0.5 µg/mL	Phytophthora capsici	[77]
				Murranolide A	Oxygenated polyketide	IC50 50–100 µg/mL
				Murranopyrone	Dihydropyrones	50–100 µg/mL
				Murranoic acid A	Dienoic acid	50–100 µg/mL
Fusarium sp.	Hyphomycetes	Mentha longifolia	AntimalarialAntifungal	Fusaripeptide A	Cyclodepsipeptide	IC50 0.24 µM0.11 µM	C. glabrata C. albicans	[78]
Trichothecium sp.	Hyphomycetes	Phyllanthus amarus	Anticancer, Antimetastatic,Antifungal	Trichothecinol A	Trichothecenes	20 µg/mL (MIC)	Cryptococcus albidusHeLa and B16F10 cellsMDA-MB-231 cells	[79]
Phoma sp.	Coelomycetes	Fucus serratus	Antimicrobial	Phomafuranol(3R)-5-hydroxymelleinPhomalactonEmodin	Dihydrofuran derivative	NR	M. violaceum	[80]
				(3R)-5-hydroxymellein		5 mm ZOI
				Phomalacton		6 mm
				Emodin		5 mm
Rhizopycnis vagum Nitaf 22	Coelomycetes	Nicotiana tabacum	Antimicrobial,Cytotoxic	Rhizopycnin D	Dibenzo-α-pyrone derivatives	IC50 9.9 µg/mL	M. oryzae	[81]
Colletotrichum sp.	Coelomycetes	Gomera	Antibacterial, Antifungal, Antialgal	Seimatoric acid	Oxobutanoic acid derivative	NR	Microbotryum violaceum	[82]
				Colletonoic acid	Benzoic acid derivative	7 mm ZOI	B. megaterium C. fusca
Xylaria sp. XC-16	Ascomycetes	Toona sinensis	Cytotoxic,Fungicidal	Cytochalasin Z28	Cytochalasins	12.5 µM (MIC)	G. saubinetti	[83]
Penicillium chrysogenum	Hyphomycetes	Cistanche deserticola	Neuroprotective	Chrysogenamide A	Macfortine alkaloids	IC50 1 × 10−4 µM	SH-SY5Y cells	[84]
				Circumdatin G
				Benzamide
				2′,3′-dihydrosorbicillin(9Z,12Z)-2,3-dihydroxypropyloctadeca-9,12-dienoate
Chaetomiumglobosum CDW7	Ascomycetes	Ginkgo biloba	Antifungal	Chaetoglobosin A	Chaetoglobosins	IC50 0.35 µg/mL	S. sclerotiorum	[85]
				Chaetoglobosin D		0.62 µg/mL
Coniothyrium sp.	Coelomycetes	Salsola oppostifolia	Antimicrobial	Coniothyrinones A	Hydroxyanthraquinone	7.5 mm ZOI	Microbotryum violaceum	[86]
				Coniothyrinones B		6 mm
				Coniothyrinones C		8 mm
				Coniothyrinones D		7.5 mm
Pestalotiopsis fici	Coelomycetes	Camellia sinensis	Antifungal	Ficipyrone A	α-pyrones	IC50 15.9 µM	Gibberella zeae	[87]
Xylaria sp. strain F0010	Ascomycetes	Abies holophylla Garcinia hombroniana	Antioxidant	Griseofulvin	Indanones	IC50 18.0 µg/mL	A. mali	[88,89]
						5.0 µg/mL	B. cinerea
						1.7 µg/mL	Colletotrichum gloeosporioides
						11.0 µg/mL	Corticium sasaki
						30.0 µg/mL	F. oxysporum
						1.7 µg/mL	M. grisea
Phaeoacremonium sp.	Hyphomycetes	Senna spectabilis	Antifungal	Isoaigialone B Isoaigialone C	Lactone derivatives	5 µg >5 µg	Cladosporium cladosporioides C. sphaerospermum	[90]
				Aigialone		5 µg
Aspergillus terreus	Hyphomycetes	Carthamus lanatus	Anti-microbial, Anti-malarial, Anti-leishmanial	(22E,24R)-stigmasta-5,7,22-trien-3-β-ol	Butyrolactones	IC50 4.38 µg/mL	C. neoformans	[91]
				Aspernolides F		5.19 µg/mL
Penicillium raciborskii	Hyphomycetes	Rhododendron tomentosum	Antifungal	Outovirin C	Bridged epipolythiodiket-opiperazines	0.38 µM (MIC)	F. oxysporum B. cinerea V. dahlia	[92]
Mycosphaerella sp.	Ascomycetes	Eugenia bimarginata	Antifungal	2-amino-3,4-dihydroxy-2-25-(hydroxymethyl)-14-oxo-6,12-eicosenoic acid	Eicosanoic acids	1.3 to 2.50 µg/mL (MIC)	C. neoformans C. gattii	[93]
				Myriocin		0.5 µg/mL
Guignardia sp.	Ascomycetes	Euphorbia sieboldiana	Antifungal	Guignardone N	Meroterpenes and dioxolanone derivatives	FIC 0.23	C. albicans	[94]
				Guignardic acid		0.19
Hyalodendriella sp.	Ascomycetes	Populus deltoides Marsh × P. nigra L.	Antimicrobial	Hyalodendriol C	Dibenzo-α-pyrones	19.22–98.47 μg/mL (MIC)	Bacillus subtilis Pseudomonas lachrymans Ralstonia solanacearum Xanthomonas vesicatoria Magnaporthe oryzae	[95,96]
				Palmariol B		16.18–92.21 μg/mL
				TMC-264		16.24–85.46 μg/mL
				Penicilliumolide B		17.81–86.32 μg/mL
				Alternariol 9-methyl ether		107.19–123.19 μg/mL
Fusarium sp.	Hyphomycetes	Ficus carica	Antifungal	Helvolic acid methyl ester	Helvolic acid derivative	12.5–25 μg/mL (MIC)	B. cinereaC. gloeosporioidesF. oxysporum f. sp. niveum Fusarium graminearum Phytophthora capsici	[97]
				Helvolic acid
				Hydrohelvolic acid
Lopherdermium nitens DAOM 250027	Ascomycetes	Pinus strobus	Antifungal	Six phenolic bisabolane-type sesquiterpenoids	Phenolic bisabolane-type sesquiterpenoids	50 μM (MIC)	Microbotryum violaceum	[98]
				Pyrenophorin	Macrolide	5 μM	Saccharomyces cerevisiae
Epicoccum sp.	Ascomycetes	Theobroma cacao	Antimicrobial, Antifungal	Epicolactone	Polyoxygenated polyketides	20–80 μg per paper disc (MIC)	Pythium ultimum Aphanomyces cochlioides Rhizoctonia solani	[99]
				Epicoccolide A
				Epicoccolide B
Botryosphaeria dothidea KJ-1	Ascomycetes	Melia azedarach	Antifungal,Antibacterial,Antioxidant Cytotoxic	Stemphyperylenol	α-pyridone derivativeCeramide derivative	1.57 μM (MIC)	Alternaria solani	[100]
				Pycnophorin		6.25–25 μM
				Chaetoglobosin C
				Djalonensone
				Alternariol
				β-sitosterol glucoside
				5-hydroxymethylfurfural
Botryosphaeria sp. P483	Ascomycetes	Huperzia serrata	Antifungal,Nematicidal	Botryosphaerin H	Tetranorlabdane diterpenoids	ZOI 9, 7, 7, 8, 8 mm	Gaeumannomyces graminis Fusarium solani Pyricularia oryzae Fusarium moniliforme F. oxysporum	[101]
				13,14,15,16-tetranorlabd-7-en-19,6β:12,17-diolide		12, 10, 10, 11, 13 mm
Colletotrichum gloeosporioides	Coelomycetes	Michelia champaca	Antifungal	2-phenylethyl 1H-indol-3-yl-acetate	----	5 µg25 µg (MIC)	Cladosporium cladosporioides C. sphaerospermum	[102]
				Uracil
				Cyclo-(S*-Pro-S*-Tyr) Cyclo-(S*-Pro-S*-Val) 2(2-aminophenyl) acetic acid
				4-hydroxy-benzamide
				2(2-hydroxyphenyl) acetic acid
Phoma sp. WF4	Coelomycetes	Eleusine coracana	Antifungal	Viridicatol	Viridicatol alkaloid	ZOI 1.8 mm	Fusarium graminearum	[103]
				Tenuazonic acid	Tenuazonic acid	2 mm
				Alternariol	Alternariol	1.5 mm
				Alternariol monomethyl ether	Ether derivative	1.5 mm
Chaetomium cupreum ZJWCF079	Ascomycetes	Macleaya cordata	Antifungal	Ergosta-5,7,22-trien-3beta-ol	NR	EC50 125 µg/mL190 µg/mL	Sclerotinia sclerotiorum B. cinerea	[104]
Microsphaeropsis sp.	Coelomycetes	Salsola oppositifolia	Antifungal	Microsphaerol	Polychlorinated triphenyl diether	ZOI 9 and 5 mm9 and 7 mm8 and 3 mm	Microbotryum violaceum B. megaterium E. coli	[105]
Seimatosporium sp.				Seimatorone	Naphthalenederivative
Mycosphaerella sp.	Ascomycetes	Eugeniabimarginata DC.	Antifungal	2-amino-3,4-dihydroxy-2-25-(hydroxymethyl)-14-oxo-6,12-eicosenoic acid	Eicosanoic acid	1.3–2.50 µg/mL (MIC)	C. neoformans C. gattii	[93]
				Myriocin		0.5 µg/mL
Pezicula sp.	Ascomycetes	Forsythia viridissima	Antifungal	Mellein	NR	EC50 48.63 µg/mL	B. cinerea	[106]
						150.90 µg/mL	Colletotrichum orbiculare
						163.37 µg/mL	Verticillium dahliae
						159.09 µg/mL	Fusarium oxysporium f. sp.
						118.83 µg/mL	Cucumerinum
						161.04 µg/mL	Pyricularia oryzae
						125.36 µg/mL	Pestalotia diospyri
						205.01 µg/mL	Pythium ultimum
						45.98 µg/mL	Sclerotinia sclerotiorum
Nodulisporium sp. A21	Ascomycetes	Ginkgo biloba	Anti-phytopathogenic,Antifungal	Sporothriolide	NR	EC50 3.04 µg/mL200 µg/mL	Rhizoctonia solani Magnaporthe oryzae	[107]
Echinacea purpurea	Ascomycetes	Biscogniauxia mediterranea EPU38CA	Antifungal	(−)-5-methylmellein	NR	300 µM (MIC)	P. obscurans	[108]
						----	P. viticola
				(−)-(3R)-8-hydroxy-6-methoxy-3,5-dimethyl-3,4-dihydroisocoumarin	Coumarin	----	B. cinerea
						300µM	P. viticola
						----	P. obscurans
Phialophora mustea	Ascomycetes	Crocus sativus	Antimicrobial,Cytotoxic	Phialomustin C	Azaphilone derivative	IC50 14.3 µM	Candida albicans	[109]
				Phialomustin D		73.6 µM
Plectophomella sp.Physalospora sp.	Ascomycetes	NR	Antifungal, Antibacterial, Herbicidal	(−)-Mycorrhizin A	Mycorrhizin	---	Ustilago violacea Eurotium repens	[110]
				Cytochalasins E	Cytochalasins	---	E. repens Mycotypha microspore
				Cytochalasins K
				Radicinin	Dihydropyranone	---	E. repens M. microspore
Berkleasmium sp.	Ascomycetes	Dioscorea zingiberensis	Antifungal	Diepoxin ζ	Spirobisnaphthalenes	IC50 9.1–124.5 µg/mL	M. oryzae	[111]
				Palmarumycin C11
				Palmarumycin C12
				Cladospirone B
				Palmarumycin C6
				1,4,7β-trihydroxy-8-(spirodioxy-1′,8′-naphthyl)-7,8-dihydronaphthalene
				Palmarumycin C8
Diaporthe melonis	Ascomycetes	Annona squamosa	Antimicrobial	Diaporthemins A	Dihydroanthracenone atropodiastereomers	NA	S. aureus 25697S. aureus ATCC 29213S. pneumoniae ATCC 49619	[112]
				Diaporthemins B		NA	S. aureus 25697S. aureus ATCC 29213S. pneumoniae ATCC 49619
				Flavomannin-6,6′-di-O-methyl ether		32 μg/mL (MIC)	Staphylococcus aureus 25697
						32 μg/mL	S. aureus ATCC 29213
						2 μg/mL	Streptococcus pneumoniae ATCC 49619
Cryptosporiopsis quercina	Ascomycetes	Tripterigium wilfordii	Antifungal	Cryptocandin	Lipopeptide	MIC 0.03–0.07 μg/mL	C. albicans, Trichophyton mentagrophytes, Trichophyton rubrum	[113]
Colletotrichum gloeosporioides	Ascomycetes	Artemesia mongolica	Antifungal	Colletotric acid	Benzoic acid derivative	MIC 25 μg/mL	Bacillus subtilis	[114]
						50 μg/mL	Staphylococcus aureus
						50 μg/mL	Sarcina lutea
						50 μg/mL	Helminthosporium sativum
Alternaria sp.	Ascomycetes	Trixis vauthieri	Anti-trypanosomiasis, Anti-leishmaniasis	Altenusin	Biphenyl fungal metabolite	IC50 4.3 μM	Trypanothione reductase (TR) inhibitory activity	[115]
Aspergillus sp. strain CY725	Hyphomycetes	NR	Antibacterial	Helvolic acid	Helvolic acid	8.0 µg/mL (MIC)	H. pylori	[116]
				Monomethylsulochrin		10.0 µg/mL
				Ergosterol	Sterols	20.0 µg/mL
				3b-hydroxy-5a, 8a-epidioxy-ergosta-6, 22-diene		30.0 µg/mL
Fusarium sp. IFB-121	Hyphomycetes	Quercus variabilis	Antibacterial	Fusaruside	Cerebrosides	3.9 µg/mL (MIC)	B. subtilis	[117]
						3.9 µg/mL	E. coli
						1.9 µg/mL	P. fluorescens
				(2S,2′R,3R,3′E,4E,8E)-1-O-beta-D-glucopyranosyl-2-N-(2′-hydroxy-3′-octadecenoyl)-3-hydroxy-9-methyl-4,8-sphingadienine		7.8 µg/mL	B. subtilis
						3.9 µg/mL	E. coli
						7.8 µg/mL	P. fluorescens
Periconia sp.	Ascomycetes	Taxus cuspidata	Antibacterial	Periconicins A	Fusicoccane diterpenes	3.12 µg/mL (MIC)	Klebsiella pneumoniae	[118]
				Periconicins B		25 µg/mL
F. oxysporum	Hyphomycetes	Lycopersicum esculentum	Nematicidal	3-hydroxypropionic acid	Propionic acid	LD50 12.5–15 µg/mL	M. incognita	[119]
Chaetomium sp.	Ascomycetes	Nerium oleander	Antioxidant	NR	NR	IC50 109.8 μg/mL	Inhibited xanthine oxidase activity	[120]
Cladosporium cladosporioides	Ascomycetes	Huperzia serrata	Prevent neurodegeneration	Huperzine A	NR	10 μg/mL	Acetylcholinesterase inhibition activity	[121]
Edenia sp.	Ascomycetes	Petrea volubilis	Antiparasitic	Palmarumycin CP17	NR	IC50 1.34 μM	Leishmania donovani	[122]
				Palmarumycin CP18		0.62 μM
Nodulisporium sp.	Ascomycetes	Erica arborea	Antifungal, Antialgal	Nodulisporins D	Naphthalene-Chroman Coupling products	ZOI 8 mm	B. megatarium	[123]
						7 mm	M. violaceum
						8 mm	C. fusca
				Nodulisporins E		7 mm	B. megatarium
						7 mm	M. violaceum
						5 mm	C. fusca
				Nodulisporins F		8 mm	B. megatarium
						10 mm	M. violaceum
						8 mm	C. fusca
				(3S,4S,5R)-2,4,6-trimethyloct-6-ene-3,5-diol		0 mm	B. megatarium
						8 mm	M. violaceum
						6 mm	C. fusca
				5-hydroxy-2-hydroxymethyl-4H-chromen-4-one		0 mm	B. megatarium
						6 mm	M. violaceum
						6 mm	C. fusca
				3-(2,3-dihydroxyphenoxy)-butanoic acid		0 mm	B. megatarium
						6 mm	M. violaceum
						7 mm	C. fusca
Chalara sp.	Ascomycetes	Artemisia vulgaris	Antibacterial	Isofusidienol A	Chromone-3-oxepines	ZOI 23 mm	B. subtilis	[124]
				Isofusidienol B		22 mm
				Isofusidienol C		9 mm
				Isofusidienol D		8 mm
Ampelomyces sp.	Ascomycetes	Urospermum picroides	Cytotoxic	6-O-methylalaternin	NR	41.7 μM (MIC)	S. aureus S. epidermidis Enterococcus faecalis	[125]
				Altersolanol A		37.2–74.4 μM
Alternaria sp.	Ascomycetes	Sonneratia alba	Antibiotic	Xanalteric acid I	Phenolic compounds	343.40–686.81 μM	S. aureus	[126]
				Xanalteric acid II
Pestalotiopsis theae	Coelomycetes	---	Anti-HIV	Pestalotheol A	NR	NR	HIV-1LAI replication in C8166 cells	[127]
				Pestalotheol B		NR
				Pestalotheol C		EC50 16.1 μM
				Pestalotheol D		NR
Stemphylium globuliferum	Ascomycetes	Mentha pulegium	Cytotoxic	Alterporriol G and H (mixture)	NR	EC50 2.7 μM	L5178Ylymphoma cells	[128]
				Altersolanol K
				Altersolanol L
				Stemphypyrone
Chaetomium sp.	Ascomycetes	Otanthus maritimus	Cytotoxic	Aureonitolic acid	Tetrahydrofuran derivative	NA	L5178Y mouse lymphoma cells	[129]
				Cochliodinol		EC50 7.0 μg/mL
				Isocochliodinol		---
				Iindole-3-carboxylic acid		---
				Cyclo(alanyltryptophane)		---
				Orsellinic acid		2.7 μg/mL
Chaetomium sp.	Ascomycetes	Eucalyptus exserta	Antibacterial	Mollicellin O	Depsidones	IC50 79.44 μg/mL	S. aureusATCC29213	[130]
						76.35 μg/mL	S. aureus N50
				Mollicellin H		5.14 μg/mL	S. aureusATCC29213
						6.21 μg/mL	S. aureus N50
				Mollicellin I		70.14 μg/mL	S. aureusATCC29213
						63.15 μg/mL	S. aureus N50
			Cytotoxic	Mollicellin G		19.64 μg/mL	HepG2 cell line
						13.97 μg/mL	Hela cell line
				Mollicellin H		6.83 μg/mL	HepG2 cell line
						---	Hela cell line
			Antioxidant	Mollicellin I		---	HepG2 cell line
						21.35 μg/mL	Hela cell line
				Mollicellin O		71.92 μg/mL	DPPH free radical scavenging assay
Alternaria sp.	Ascomycetes	Polygonum senegalense	Cytotoxic	Alternariol	Sulfated derivatives of alternariol and its monomethyl ethers	EC50 1.7 μg/mL	L5178Y lymphoma cells	[131]
				Alternariol 5-O-sulfate		4.5 μg/mL
				Alternariol 5-O-methyl ether Altenusin Desmethylaltenusin		7.8 μg/mL
				2,5dimethyl-7-hydroxychromone Tenuazonic acid		6.8 μg/mL
				Altertoxin I		6.2 μg/mL
				3′-hydroxyalternariol 5-O-methyl ether		---
				Alterlactone		---
				Alternaric acid		---
				Talaroflavone		---
				Altenuene		---
				4′-epialtenuene		---
Phyllosticta spinarum	Ascomycetes	Platycladus orientalis	Cytotoxic	Tauranin(+)-(5 S,10 S)-4′-hydroxymethylcyclozonarone	Sesquiterpene quinones	EC50 4.3 μM	NCI-H460 cell linesMCF-7 cell linesSF-268 cell linesPC-3 M cell linesMIA Pa Ca-2cancer cell lines	[132]
				3-ketotauranin		1.5 μM
				3alpha-hydroxytauranin		1.8 μM
				12-hydroxytauranin		3.5 μM
				Phyllospinarone		2.8 μM
Eupenicillium sp.	Ascomycetes	Glochidion ferdinandi	Cytotoxic	Trichodermamide C	A modified dipeptide	IC50 1.5 μM	Humancolorectal carcinoma cell line HCT116	[133]
						9.3 μM	Human lungcarcinoma cell line A549
Pestalotiopsis sp.	Coelomycetes	Rhizophora mucronata	Cytotoxic	Pestalotiopsone F	Pestalasinschromones	EC50 26.89 μM	Murine cancer cell line L5178Y	[134,135]

Abbreviations: ZOI, Zone of Inhibition; MIC, Minimum Inhibitory Concentration; IC50, Inhibitory Concentration T 50%; EC50, Effective Concentration at 50%; LD50, Lethal Dose Concentration at 50%; FIC, Fractional Inhibitory Concentration; NR, Not Reported; NA, Not Active.

Endophytic fungi produce diverse kinds of bioactive metabolites and are categorized as terpenoids, indole alkaloids, polyketides, and non-ribosomal peptides [136] biosynthesized via different routes. Terpenoids (composed of multiple isoprene units) are biosynthesized via the mevalonate pathway by terpene cyclases, biosynthesis of cyclic terpenes by diterpene cyclase and sesquiterpene cyclases, indole diterpenes by prenyl transferases, and carotenoid formation by phytoene synthases [137]. While indole alkaloids are biosynthesized via the shikimic pathway, polyketides by polyketide synthases from acetyl-CoA and malonyl-CoA units, and nonribosomal are formed independently of ribosomes function by NRPS enzymes, different categories of fungal metabolites originate via different biosynthetic routes [137]. The different categories of metabolites are further classified as flavonoids, coumarins, xanthones, quinones, lignans, and others and demonstrate multifaceted applications. The plethora of bioactive compounds and their analogs have displayed potential pharmacological activities in animal models and as herbal medicines against several human ailments. With scientific breakthroughs in high-throughput technologies and whole-genome sequencing, natural products from endophytes have been explored as alternative sources of novel drug-like candidates, among the 1562 FDA approved drugs, there were 64 original natural products, and 320 drugs were derivatives of natural products [5]. In addition, the development of new technologies has substantially contributed to the re-establishment of drying pipelines for novel candidates in drug discovery programs. The availability of complete genomes of endophytes and the enormous amount of information on different endophyte strains have provided remarkable insights into the molecular mechanisms of endophyte colonization and interaction with the host plant.

The bio-prospection of endophytic fungi suggests that very few fungal strains have been studied in-depth, with others highlighting the potential for the existence of enormous novel candidates. The dominant taxonomic categories for the synthesis of chemical entities are from the orders Ascomycota (~97%), Basidiomycota (~2%), and Mucoromycota (~1%), and the key metabolite-rich strains include Fusarium, Aspergillus, Penicillium, and Alternaria [59,138]. The presence of high-value (anticancer) compounds in endophytic fungi includes novel chemical entities such as terpenoids and steroids (integracides), polyketides (phomones), nitrogen-containing heterocycles (penicisulfuranols), and ester quinones [138]. Other studies have reviewed and reported the presence of metabolites for tropical diseases (including altenusin, viridiol, and cochlioquinone) [139], metabolites mimicking plant secondary metabolites (antioxidant resveratrol), antidiabetics (rohitukine), anticancer (taxol), antihypercholesteromics (lovastatin), and others [140,141]. Several other metabolites of socio-economic importance were identified from endophytic fungi between 2010 and 2017 [141,142]. Among the diverse metabolites, a few significant ones produced from endophytic fungi include saponins as nutraceuticals [143], loline alkaloids as bioinsecticides [144], chitosan as a food additive [145], taxol as a pharmaceutical [146], fatty acids as ingredients in cosmetics [145], and ascotoxin as bioherbicides [147], among others. In a remarkable study, Harpar et al. [148] predicted the relative stereochemistry of ambuic acid, isolated from the endophytic fungi, Pestalotiopsis microspora. The novel solid-state NMR approach led to structural elucidation and a dimeric structure was suggested for ambuic acid, consisting of a hydrogen-bonded adjacent carboxyl group, including the lattice structure details, an excellent study performed for the first time on a natural product.

Furthermore, the quorum-sensing activity of ambuic acid in Gram-positive bacteria suggested its development as a potent antipathogenic drug for targeting the virulence expression of Gram-positive bacteria. The compound, ambuic acid, inhibited quorum sensing in bacteria via the inhibition of gelatinase biosynthesis-activating pheromone (GBAP) biosynthesis [149]. Another interesting area in bioactive metabolites from Muscodor spp. has gained momentum in multi-faceted applications. Diverse types of volatile organic compounds (VOCs) are produced by Muscodor spp. and comprise aldehydes, aromatics, esters, alcohols, terpenoids, and nitrosamides, among others [150]. The endophytic genus highlights multi-faceted attributes in industrial and agricultural applications, followed by food and healthcare, projecting direct and indirect applications. The diverse application of VOCs, isolated from Muscodor spp., includes agricultural applications (antimicrobial agents, for soil fumigation, biofumigation, etc.), food preservation, the perfume industry, and bioactive compounds in healthcare [150]. In addition, non-ribosomal peptides (NRP) and Penicillin (antibiotic) were isolated from a mangrove endophytic fungus, Penicillium chrysogenum MTCC 5108 [151]. Similarly, a polyketide synthase I (PKS I)-based screening method led to the discovery of a new polyketide, penicitriketo from endophytic fungi [152].

Plant-associated endophytes have gained significant momentum in bio-prospection and isolation of bioactive metabolites with multi-faceted attributes. In this direction, literature reviews have provided key insights into the existing and emerging significance of endophytes in drug discovery and research—a few articles worth mentioning include Discussion on biodiversity of endophytes and its exploitation in drug discovery [1], Bioactive metabolites, and their pharmaceutical design in drug development [2], Emerging roles and applications of actinomycetes endophytes [13], Chemical ecology of endophytes and its role in bioactive metabolite production [43], The process of horizontal gene transfer and its implications in the transfer of novel traits in production of bioactive metabolites [56], and comprehensive insight on the diverse metabolites produced by fungal endophytes and their biological functions, among others. The present review on fungal endophytes provides a detailed insight into the existing and emerging prospects of fungal endophytes as “novel candidates” in drug discovery and research and how the different yield enhancement strategies can be adopted to address the associated bottlenecks and enhance bioactive metabolite production.

3. Molecular Mechanisms of Plant–Endophytic Fungi Interactions

Evolutionary studies have suggested an important role of fungal partners in plant adaptation/colonization in terrestrial systems [153]. Several studies have documented the beneficial role of plant-associated endophytic fungi [29,154]; however, biological and chemical barriers need to be addressed to establish plant–fungal associations [43]. The theory of “balanced antagonism” ensures a balanced equilibrium between the adverse effects of endophyte association with plant hosts and the defense response exerted by the plants [155]. To ensure survival within plant hosts, endophytes secrete secondary metabolites that neutralize the toxic effects of plant host defense. Moreover, the invasion of endophytes into plants activates the plant defense system, limiting endophyte development and disease symptoms, if any. Asymptomatic colonization by endophytes is mediated by metabolite production, which counters host defense via multipartite symbiosis [155,156]. The phenomenon of “balanced antagonism” with the competent existing microbes is further adopted by endophytic fungi, balancing plant defense and virulence of endophytic fungi. However, if the plant host defense is overcome by endophytic fungi, it will lead to plant disease via plant–pathogen interactions [157]. A key example of this phenomenon is the production of taxol by Paraconiothyrium SSM001 to tackle host pathogens [61]. Furthermore, the coevolution of endophytes and plant hosts has resulted in the development of sophisticated mechanisms by endophytes to modify plant immune responses [158], such as the suppression of β-glucan-triggered immunity by endophytes in multiple plants [159]. In terms of plant hosts, the evolution of defense mechanisms, including secondary metabolite production to counter pathogens, constitutes an integral host mechanism. In response to this, pathogens have developed resistance mechanisms and undergone structural modifications in some cases to counter plant defense responses [157]. An interesting mechanism displayed by endophytes within plants is promoting plant immunity by monitoring the vascular system; for example, in Pacific yew, known for taxol production by endophytic fungi, the pathogens enter the vascular system through air pockets and cracks in the bark, and the endophytes release taxol as a defense barrier to pathogens [61].

Recent advances in scientific interventions and whole-genome sequencing have contributed substantially to the bio-prospection of endophytic fungi to produce pharmacological metabolites. Endophytic fungi and their metabolic pathways are key targets for research. Although the metabolic pathway has defined a genetic framework to produce a specific metabolite, gene clusters mostly remain silent under laboratory conditions [3]. Moreover, strategies to activate silent gene clusters through co-cultivation of different endophytic fungal strains, mutagenesis, and genetic engineering have been adopted to improve the biosynthetic potential of different endophytic strains, with limited success. Moreover, the bioactive metabolites isolated from endophytic fungi are classified into different categories, including phenolics, flavonoids, saponins, alkaloids, terpenes, and xanthones [160], demonstrating multiple pharmacological properties. However, the decreased production due to repeated sub-culturing of the microbial strains leads to an unstable yield in axenic cultures, which accounts for the few existing challenges in endophyte biology and research. Different researchers have proposed parallel hypotheses on the genetic origin of metabolites (both in endophytes and plants), including the presence of parallel biosynthetic pathways for metabolite production in plants and endophytes. However, examples of taxol gene clusters showed low similarities between plants and microbes [161], suggesting an independent evolution of biosynthetic pathways in different organisms [162]. Another key example is camptothecin (CPT) production by Fusarium solani utilizing the host enzyme strictosidine synthase for CPT biosynthesis, suggesting the horizontal transfer of gene clusters between endophytic fungi and host plants in an evolutionary course [163]. Both endophytic fungi and plants possess resistance mechanisms against CPT and taxol, respectively. Another independent hypothesis claims that host mimicking by endophytic fungi leads to the production of bioactive compounds, such as plant hosts, questioning the actual biosynthesis by endophytic fungi [43]. However, limited knowledge about the molecular mechanisms of plant–associated endophytic fungi is a major challenge in the large-scale commercial production of bioactive metabolites from endophytic fungi.

4. Scientific Approaches for Natural Product-Based Drug Discovery

Key strides have been made in the discovery and characterization of valuable bioactive metabolites from natural sources. Substantial efforts to identify novel bioactive metabolites have opened new avenues in natural product-based drug discovery from endophytic fungi. The increasing importance of natural products in pharmacological applications has greatly impacted the large-scale production of high-value metabolites. Plant–microbe associations, particularly endophytic fungi, continue to intrigue researchers worldwide with a considerable potential to impact the pharmaceutical industry [164,165]. With the alarming rise in AMR and declining drug pipelines, novel metabolites from natural sources are increasingly being studied for their therapeutic potential. In this direction, advances in high-throughput technologies and scientific interventions have provided firm grounds as “discovery platforms” in natural product-based drug discovery programs. In addition, the emerging revolution in interdisciplinary strategies comprising computational methods and multi-omics strategies has redefined natural product discovery from plant–endophytic associations [166]. Figure 2 provides a schematic overview of the traditional and emerging scientific approaches for endophyte-based drug discovery.

Figure 2

Provides a schematic overview of the traditional and emerging scientific approaches for endophyte-based drug discovery (Created with BioRender.com, accessed on 24 January 2022).

5. Traditional Scientific Methods

Recently, there has been an increased exploration of plant–endophytic associations for the discovery of high-value metabolites with potential pharmacological applications. Deep learning methods have defined an interesting platform for the bio-prospection of endophytes, regulatory networks, and the prediction of novel chemical entities [166]. As discussed earlier, plant-associated endophytes have defined an attractive “biosynthetic platform” for the synthesis of novel bioactive metabolites; however, several challenges exist in harnessing these biological sources in drug discovery. For example, most of the secondary metabolite pathways are silenced, and the knowledge of metabolic networks and mechanisms needs to be understood in detail. Furthermore, in silico approaches predict the existence of a wide array of metabolites that remain silent/inactive under native conditions (in planta) [167,168]. In recent decades, natural product discovery from endophytes relied on powerful, low-throughput methods [3], essentially including culture-based methods, plant-based extraction methods, biochemical screening/isolation using HPLC, NMR, and MS, and bioactivity-guided isolation [169], with existing limitations. Toward addressing the existing challenges, sophisticated methods, namely the “one strain-many compounds” (OSMAC) approach, engineering ribosomes, heterologous expression of genes, and promoter studies have been widely explored [170]. The OSMAC method is based on studying a particular strain and its growth under different culture conditions to produce a diverse array of metabolites [168]. These promising tools enhance gene expression in endophytes via biotic/abiotic triggering mechanisms.

Another interesting strategy is the co-cultivation of different endophytic fungal strains to elicit gene expression in silent gene clusters [171]. For example, gene expression for taxol production was reclaimed in Aspergillus terreus when co-cultivated with Podocarpus gracilior leaves [172]. Furthermore, genetic methods have been successful in activating silent BGCs and include inducible/constitutive promoters [173], host ribosome engineering [174], and mutant selection [175]. In addition, for culturable endophytic bacteria, some important high-throughput techniques used include high-throughput elicitor screening with imaging mass spectrometry, with the potential to induce silent gene clusters [176], and most techniques were effective for culturable microbes only.

6. Deep Learning Approaches

One of the key approaches for analyzing large data comprises artificial intelligence, further classified as deep learning and machine learning. These methods predict the distribution pattern of the plant microbiome (environmental niches) and may accurately predict the biosynthesis of bioactive metabolites from endophytes [177], highlighting a potential approach to replace challenging global, comprehensive estimation. In this approach, the initial dataset could be obtained from the increasing multi-omics and genomics combined with plant metabolomics data. The targeted region can then be analyzed through multi-omics methods, further co-integrated with metabolic pathway analysis [178,179,180]. Currently, multiple deep learning and machine learning strategies are employed to improve drug discovery from natural products. The software DeepBGC relies on a word2vec-like word embedding skip-gram neural network and bidirectional long short-term memory (BiLSTM) neural network, subject to a large dataset from microbial communities [181]. Furthermore, bio-prospection of endophytes for bioactive metabolites may be performed by integrating genome metabolic models and deep learning methods. Similarly, for the diversity prediction of chemical entities, deep learning chemi-informatics methods may be employed for efficient prediction. In addition, computational biology methods emphasize the analysis of chemical entities and metabolomics strategies, targeting a predictive model of plant microbiome and associated biochemical changes. In keeping with the target goal, the abovementioned deep learning methods may be suitably altered; for example, the objective may be to find chemical novelty or a target function (antimicrobial) or elucidation of complex structures [166]. The established genome mining tools aim to understand metabolic flux and pathway regulation, regulatory processes, and metabolite interactions. With the enormous amount of data generated from high-throughput experiments, the OSMAC tool, co-integrated with metabolomics information, forms a basis for computational analysis. These novel computational pipelines project revolutionary landmarks in natural product-mediated drug discovery from endophytes.

7. High-Throughput Strategies

Advances in computational biology and whole-genome sequencing have been instrumental in defining new avenues for endophyte-mediated natural product discovery. Comparative genomics aims to understand the diversity of chemical entities from microbes because of the conserved BGCs across species, associated with regulatory genes, uptake, and product transport [166]. Moreover, BGCs, which are specific, are mostly silent/lowly expressed under laboratory conditions, making functional gene prediction difficult. An effective approach toward the discovery of natural products begins with in silico predictions through genome information and proceeds to experimental validation via activation of the biosynthetic pathways [178]. The ongoing efforts in the development and upgradation of computational resources have greatly refined research on natural product-mediated drug discovery. Databases such as the Database of BIoSynthesis clusters CUrated and InTegrated (DoBISCUIT) [182], and ClustScan software [183], and ClusterMine 360 [184] have facilitated the discovery/identification of novel gene clusters. Moreover, the discovery of BGCs via phylogenetic analysis was performed through a useful database, The Minimum Information on Biosynthetic Gene clusters (MIBiG) [185]. Other bioinformatics databases promoting the annotation of BGCs include Reconstruction, Analysis and Visualization of Metabolic Networks’ RAVEN 2.0 software [186], antibiotics and secondary metabolite analysis shell (antiSMASH) [187], and Metaflux [188], and the genome-wide identification and profiling of gene clusters of natural products have become attainable. In addition, bioinformatics software (based on the network algorithm) improves predictions of genome mining methods [189] and may be co-integrated with metabolic modeling approaches [190]. The predictive strategies further extend the understanding of metabolic interactions in microbial cultures [191], bio-kinetic models for the estimation of interspecific interactions among microbes [192], single-cell analysis for endophyte metabolism [192] and transcriptome approaches for comprehensive understanding [193].

8. Pharmacological Metabolites: Case Studies, Mechanism of Action, and Commercial Success

Medicinal plants form the backbone of the traditional system of medicine and are a rich source of pharmacological metabolites for the treatment of diseases and prospects as modern medicines [56]. Since the initial reports of taxol production from the endophyte Taxomyces andreanae, similar to its plant host (Taxus brevifolia) in 1993, endophytes have been increasingly explored for the production of high-value metabolites. Plant-associated endophytes, particularly endophytic fungi, have emerged as production platforms for pharmacological metabolites with diverse therapeutic applications [2]. There has been an upsurge in the production and marketing of pharmacological metabolites worldwide, and a few remarkable examples and their success stories in the pharmaceutical sector have been discussed. Table 3 presents key examples of commercially available drugs from endophytic fungi: key examples, pharmacological functions, bottlenecks, and success stories.

Table 3

Commercially available drugs from Endophytic fungi: key examples, pharmacological function, bottlenecks, and success stories.

Marketed Drug			Commerical Market	Endophyte	Pharmacological Functions	Bottlenecks	References
Taxol (Paclitaxel)			$78.77 million (2017)	Taxomyces andreanae Taxus brevifolia	Anticancer-binds to microtubule assembly and delays cell division/growth,Treatment for breast, ovary, and Kaposi’s sarcoma	Biosynthetic complexities, harvestation of the molecule	[15,194,195]
Camptothecin			$2.2 billion (2008)	Entrophospora infrequensAlternaria alternataFomitopsis sp. Phomopsis sp.	Inhibitor of Topoisomerase enzyme	Yield-loss on repeated sub-culturing	[196,197]
	R	R1
Camptothecin (2)	H	H
9 Methoxycamptothecin (3)	OCH3	H
10-Hydroxycamptothecin (4)	H	OH
Vinca alkaloids (Vinblastine and Vincristine)			-	Alternaria sp.F. oxysporum	Anticancer alkaloids, inhibit microtubule assembly leading to destabilization	Yield-loss on repeated sub-culturing	[198,199]
Podophyllotoxin			$444.1 million (2019)	Phialocephala fortinii	Cytotoxic in U-87 cell line, Antitumor activity in cancer models	Low abundance in plants	[200,45]
Griseofulvin			$5.8 billion (2019)	Xylaria sp. strain F0010	Antioxidant	Low abundance, production from alternate sources	[89]
Laritin A and B			-	Rhodococcus jostii	Anti-inflammatory, Anticancer, Immunomodulatory properties	Low abundance, Yield-loss on repeated sub-culturing	[13]
Rohitukine			-	Fusarium proliferatum	Cytotoxic against the HCT-116 and MCF7 cell lines	Yield-loss on repeated sub-culturing	[201]
Piperine			$4.87 billion (2020)	Periconia strains	HepatoprotectiveAntibacterial	Yield-loss on repeated sub-culturing	[202] https://www.expertmarketresearch.com/reports/piperine-market accessed on 12 July 2021
Altersolanol			-	Alternaria sp.	Antiangiogenic	Yield-loss on repeated sub-culturing	[203]
Huperzine A			-	Shiraia sp.	Cholinesterase inhibitor	Yield-loss on repeated sub-culturing	[204]
Phomoxanthone A and B			-	Phomopsissp., BCC 1323	Cytotoxic against BC-1 cells, KB, and Vero (non-malignant) cells	Yield-loss on repeated sub-culturing	[205]
Quinine			$804.98 million	Phomopsis sp.	Antimalarial agent	Yield-loss on repeated sub-culturing	[206]https://www.prnewswire.com/news-releases/global-quinine-market-review-2015-2018 accessed on 12 July 2021
Silybin A			-	Aspergillus iizukae	Hepatoprotective	Low abundance, production from alternate sources	[207]

9. Taxol Production

The anticancer drug taxol is one of the most successful drugs marketed globally for its anticancer activity. Taxol was isolated from the medicinal plant Taxus brevifolia, but its concentration was too low (0.001–0.05%) in most species. Therefore, 1 g of taxol production requires 15 kg of tree bark, while the anticancer dose amounts to 2.5 g [208]. To increase taxol production, alternative sources have been investigated to meet the rising therapeutic demands. The bioactive metabolite, taxol was first isolated from the endophytic fungi Taxomyces andreanae [209], and subsequently from other endophyte species. The discovery (in 1960), structural elucidation (1971), and FDA approval (1992) of taxol defined new paradigms in global commercial success, projecting a global market of USD 78.77 million in 2017. In chemotherapies for cancer treatment, paclitaxel is a mitosis inhibitor and is widely used for the treatment of cancers such as cervical, ovarian, and breast cancers. The global consumption trends indicated a market share of 53% (2017), with Europe accounting for 19% of global market trends [210].

Taxol and its derivatives represent a popular class of anticancer drugs produced by different endophytes. The mechanism of action includes inhibition of mitosis and promotion of tubulin depolymerization during cell division [211]. After several research attempts, the taxol-producing endophyte T. andreanae was discovered in Taxus brevifolia, detected via electrospray mass spectroscopy [212] and compared with the standard paclitaxel. The identification of taxol and its anticancer potential was bright, but the existing crisis and the low content in the plant projected major concerns to increase supply. Subsequently, paclitaxel-producing endophytes have been reported (taxol-producing endophytes from Taxus baccata L.), characterized, and validated using HPLC-MS [213]. The five taxol-producing endophytic fungi were Fusarium redolens, Gibberella avenacea, Fusarium tricinctum, Paraconiothyrium brasiliense, and Microdiplodia sp. G16A, with the highest taxol yield of 66.25 μg/L by Fusarium redolens [214]. The diterpenoid metabolite was further isolated from several endophytes belonging to the Ascomycota, Basidiomycota, Deuteromycota, and Zygomycota classes [215,216]. However, successful translational research towards industrial production faces certain challenges currently, including decreased production because of repeated sub-culturing and low concentration in biological species. Comprehensive knowledge of endophyte biology and dynamics is essential for improving the commercial production of important bioactive metabolites [2,217].

Presently, considering the global market for anticancer drugs, research efforts have been made for large-scale production of taxol from endophytic fungi [218,219,220]. Fermentation methods have been optimized for taxol production by supplementing nitrogen/carbon sources, precursors, and elicitors [221] and defined conditions related to temperature, pH of culture, and dissolved oxygen [222]. Moreover, inhibition of the metabolic pathway of sterols (ergosterol) by triadimefon (inhibitor) is effective in enhancing the production of paclitaxel [223]. However, taxol production in endophytic fungal cultures leads to the reprogramming of fungal physiology and the regulatory loss of metabolite production [141]. Co-cultivation of Paraconiothyrium sp. with Alternaria sp., and Phomopsis sp. enhanced taxol production eightfold [224]. Genetic transformation of endophytic fungi is an emerging method for increasing the production of targeted metabolites [220]. Protoplast-mediated transformation [225], Agrobacterium-mediated transformation [226], electroporation [227], and genome editing via CRISPR-Cas [228] are some other scientific approaches employed to enhance taxol production by endophytic fungi.

10. CPT Production

CPT is a monoterpene indole alkaloid that is commercially marketed as an anticancer drug. Initially, it was isolated from the stem and bark of Camptotheca acuminata, a native Chinese tree. CPT has a pentacyclic structure and is a topoisomerase inhibitor that binds to topoisomerase I and DNA complex and stabilizes it, leading to DNA damage and apoptosis (https://en.wikipedia.org/wiki/Camptothecin, accessed on 23 July 2021). In clinical trials, CPT showed anticancer activity against colon, lung, breast, and stomach cancers. The commercial success of CPT is attributed to its applications in cancer chemotherapies, and its derivatives are marketed with the name belotecan, topotecan, irinotecan, and trastuzumab deruxtecan [229,230]. CPT was commercially isolated from Nothapodytes nimmoniana and C. acuminata and has a high global demand for cancer treatment [231]. Although some CPT derivatives are commercially marketed (irinotecan, belotecan, and topotecan), others such as diflomotecan, tenifatecan, genz-644282, chimmitecan, exatecan, lipotecan, silatecan, cositecan, and simmitecan are under clinical trials [232,233]. The increasing demand for CPT has led to indiscriminate use/overharvesting of the two plants, making them an endangered species [234]. To produce 1 ton of CPT, approximately 1000–1500 tons of plant wood chips are required [235], leading to excessive exploitation of the plant species.

The emerging popularity of endophytes as production platforms for high-value metabolites necessitates the potential bio-prospection of endophytes for natural product drug discovery. CPT-producing endophytes have been discovered, including Trichoderma atroviride LY357 [236], Fusarium solani strain ATLOY-8 [237], and Neurospora sp. [238]. However, the variable/inconsistent production, yield loss because of sub-culturing, and low concentrations are the major bottlenecks in the commercial-scale production. Mohinudeen et al. [239] reported the presence of a high-CPT-producing endophyte Alternaria sp. from N. nimmoniana. The endophyte produced up to ~200 μg/g of CPT in axenic cultures and demonstrated cytotoxic activity against cancer cell lines [239]. Regarding the molecular pathways in CPT production, strictosidine synthase, tryptophan decarboxylase, secologanin synthase, and geraniol 10-hydroxylase are some of the key enzymes identified to date. Kusari et al. [43] identified tryptophan decarboxylase, secologanin synthase, and geraniol 10-hydroxylase in endophytic fungi. The absence of the strictosidine synthase gene in endophytes has led to the presumption of the involvement of host genes in CPT biosynthesis. Decreased CPT yield due to sub-culturing was explained by the absence of selection pressure, leading to the degradation of biosynthetic pathways in the endophytic fungi [41], limiting CPT biosynthesis. Recent advances employing endophytes as production platforms for CPT have focused on isolation/fermentation of CPT-producing endophytes, extraction, and detection via different methods, and employing fermentation culture to improve CPT yield [240].

11. Vinca Alkaloids (Vincristine/Vinblastine) Production

Vinca alkaloids are pharmacological metabolites isolated from Madagascar periwinkle (Catharanthus roseus) and are listed on the World Health Organization’s List of Essential Medicines [241]. Vinca alkaloids are used as effective medications for the treatment of different types of cancers, including bladder cancer, melanoma, and lung cancers (https://en.wikipedia.org/wiki/ accessed on 23 July 2021). Vinblastine is an analog of vincristine, and its anticancer mechanism is defined by binding to tubulin, thereby inhibiting microtubule assembly and formation, and is regarded as an effective chemotherapeutic agent. Two of the most successful commercial drugs—vinblastine and vincristine—are present at very low concentrations in plants. Moreover, the estimated global demand for bioactive metabolites (0.3 tons annually) and global market of USD 200 million projects additional requirements from alternative natural resources [242]. According to Balandrin and Klocke [243], 500 g of C. roseus leaves is required to produce 1 g of pure vincristine. Although vinca alkaloids differ slightly in their chemical structure and mechanisms, their clinical activity and toxicity vary. The commercial success and importance of vinca alkaloids have led to studies on endophytes from C. roseus. Several endophytic fungi were isolated and screened to produce vincristine/vinblastine, and a few key examples are Aspergillus, Alternaria, and Cladosporium sp. Moreover, the endophytic fungus Talaromyces radicus (from C. roseus) produced vincristine in substantial amounts (670 μg/L) in modified M2 medium and vinblastine in PDB medium (70 μg/L). Furthermore, vincristine was purified, and it demonstrated cytotoxic activity against cancer cell lines [244].

12. Podophyllotoxin Production

Another prospective pharmacologically important metabolite podophyllotoxin, an aryl tetralin lignin, is widely present in angiosperms and gymnosperms [245]. Podophyllotoxins are emerging as pharmacological metabolites because of their antiviral and cytotoxic activities [246,247]. Some semisynthetic derivatives of podophyllotoxin, teniposide, and etoposide have been approved for the treatment of leukemia and different types of cancers [248]. Because of its low concentration in plants, etoposide was developed and approved by the FDA in 1983. Other analogs were chemically synthesized but had a low yield. Research efforts to enhance the production of podophyllotoxin and its analogs from different species have been conducted. The plant tissue culture method is a reliable and sustainable approach to produce bioactive metabolites from natural sources [249]. The mechanism of action of teniposide and etoposide is marked by interaction with topoisomerase II [250] by two mechanisms: it exerts its action by enhancing topoisomerase II DNA covalent complex levels or the removal of topoisomerase II catalytic function [251]. Moreover, DNA breaks induced by enzymes promote sister chromatid exchange, recombination, translocation, and insertions/deletions [252].

Different strains of endophytic fungi have been studied for their potential to biosynthesize podophyllotoxin, and Phialocephala fortinii, endophytic fungi from Podophyllum peltatum, produced podophyllotoxin in the range of 189 and 0.5 μg/L. Furthermore, the cytotoxic potential of the endophytic fungi was evaluated, and the LD50 values were 2–3 μg/mL [200]. Another species, Fusarium oxysporum, isolated from Juniperus recurva, produced 28 μg/g of dry mass of the metabolite [253]. The bioactive metabolite has been detected/produced by several species of endophytic fungi, a few prominent ones comprise Aspergillus fumigatus from Juniperus communis [248], Trametes hirsuta from Podophyllum hexandrum [45], and Mucor fragilis [254]. The ongoing bio-prospection of different endophytic species for pharmacological metabolites highlights its existing and emerging importance in natural product-mediated drug discovery.

13. Existing/Potential Bottlenecks in Biotechnological Applications

Endophytic fungi have great potential to impact the pharmaceutical industry, subject to the bio-prospection of novel pharmacological metabolites with multifaceted implications. However, little is known about plant–endophyte dynamics, low yield, and loss of yield because sub-culturing and scaling-up cultures constitute some key bottlenecks. An emerging demand and constant supply of novel, high-value metabolites define global trends, considering the drying pipeline of antibiotic arsenals. Although the plant–endophyte interaction remains poorly understood, less information on endophytic interactions with other microbes further hampers endophyte applications. Genetic instability in plant tissue culture, slow fungal growth, and maintenance issues have decreased the use of tissue culture methods [255]. In this regard, fermentation technologies are an attractive platform to produce high-value metabolites from fungal cultures. These methods offer distinct benefits in terms of less expense, rapid growth, and optimization of culture conditions for effective production of the targeted metabolite, and sustainable production is achieved. The factors in scale-up processes, namely, oxygen solubility, viscosity of the medium, temperature, time of cultivation, pH, and others, and their optimization, make the process cumbersome. The culture conditions need to be optimized and regulated properly for the large-scale targeted production of metabolite of interest [168]. Genetic engineering approaches for the activation of BCGs for enhanced production hold potential; however, with very few reported studies on endophyte chassis, the genetic manipulation methods need to be further optimized. The combinational synthesis for complex metabolites highlights associated problems and may be resolved by employing elicitors for increased production of metabolites in a particular metabolic pathway. Other challenges include the complex structure of metabolites and undesired pathway intermediates, resulting in the inhibition of enzyme function. The existing areas of concern include the adverse effects of endophytic fungi in the control of pathogens. For example, endophytes of Crocus sativus may be pathogenic to host plant and result in infection, as endophytes are considered latent pathogens capable of causing diseases [256]. A deep understanding of the associated risk factors with endophytes is necessary to avoid adverse effects and benefit biocontrol applications.

14. Strategies for Yield Enhancement of Pharmacologically Important Metabolites

Substantial efforts to isolate and screen endophytes for high-value metabolites resulted in undesirable/low yields of the target metabolite. Although novel chemical entities such as CPT, paclitaxel, podophyllotoxin, and huperzine A were isolated from endophytic fungi, bottlenecks with large-scale production and commercialization remains a major concern. As the field of endophytes is gaining popularity in multifaceted environmental applications, scientific tools and approaches are aimed at delineating the dynamics of plant–endophyte interactions and enhancing the yield of pharmacologically important metabolites. Co-integration of bioprocess techniques and genetic/metabolomics approaches may be employed to effectively target and produce high yields of the desired metabolites.

15. Metabolic Engineering of Endophytic Fungi

Studies on the engineering of endophytes are preliminary and investigate endophyte chassis to improve the yields of targeted metabolites through genetic strategies. Genetic manipulation of endophytes defines potential future outcomes by introducing key pathway genes via genetic transformation for yield enhancement of high-value metabolites in axenic cultures. Studies on the genetic transformation of taxol-biosynthesizing endophytes include the overexpression of genes and genome rearrangement with mutagenesis for enhanced metabolite production [257,258]. Random mutagenesis approaches for genetic modification of the endophyte genome and induction of metabolites and mutant screening have been adopted [258]. Taxol production was increased (endophyte strain HDF-68) through protoplast fusion of two strains—UL50-6 and UV40-19—leading to a 20–25% increase in taxol yield [259]. Wang et al. [260] showed that the endophytic fungus Phomopsis sp. produces deacetylmycoepoxydiene (DAM) (antitumor metabolite), and genome shuffling of eight parental protoplasts resulted in a high-yielding strain (produced >200-fold DAM) in the transgenic endophytic strain [260]. Similarly, previous studies on Pestalotiopsis microspores (endophytic fungi) aimed to decode the taxol biosynthetic pathway via protoplast transformation [261]. These unexpected results led to the detection of extrachromosomal DNA in the transformants, suggesting a key role in development and adaptation. The translational success and marketing of taxol, led to extensive investigations on taxol-producing endophytes: with the application of genetic engineering defining a key platform in endophyte chassis; some important examples include, restriction enzyme-mediated integration in Ozonium sp. strain BT2 (taxol-producing fungi) [262]; Agrobacterium-mediated genetic transformation in Ozonium sp. EFY21, with enhanced efficiency of transformation [263] and PEG-mediated transformation of Ozonium sp. EFY-21 [264]. In this direction, multiple approaches for genome modification/shuffling of endophytes have been attempted to increase the metabolic flux, either by limiting competitive pathways or by reorientation of precursor supply, strain improvement methods leading to yield enhancement of targeted metabolites. In an interesting study of pathway reconstitution, the taxadiene-biosynthetic cluster was expressed in Escherichia coli and transformed into Alternaria alternata TPF6 for taxadiene production. This study was able to address the challenges associated with the first step of taxadiene production, and a consistent supply of taxadiene in A. alternata TPF6 (61.9 ± 6.3 μg/L) was obtained [265]. The inactivation of the sterol biosynthesis pathway improved the taxol yield dramatically, suggesting the prospects of genetic engineering as a means of yield enhancement of metabolites. Genome editing of filamentous fungi using the CRISPR-Cas system promises to revolutionize the production of natural products. The CRISPR-Cas9 tool aims at Cas9 gene delivery and guides DNA in cassettes and formation of active Cas9/guide RNA complex and requires markers, shuttle vectors, and promoter sequences for efficient expression. The validation of BGCs and targeted metabolite production may be improved by employing the CRISPR-Cas genome editing approach for the transformation of endophytic fungi.

16. Mutagenesis of Endophytic Fungi

To exploit endophytes on a commercial scale, it is imperative to understand and tap into the biosynthetic potential of endophytes to enhance the yield of high-value metabolites. To address the concern toward low-yielding endophyte strains, strain improvement strategies may be employed to enhance yield and other characteristics, including utilization of nitrogen/carbon sources, changes in morphology, and reduction in undesired metabolites [266]. In addition to genetic manipulations, mutagenesis of endophytes by protoplast fusion or random screening offers distinct advantages and prospects in this direction. The genetic framework of microbial strains is altered by employing mutagens and comprises either chemical (nitrosoguanidine, diethyl sulfate, ethyl methyl sulfonate) or physical (X-ray, γ-rays, microwave, etc.) mutagens. Moreover, mutant strains were analyzed using random methods to identify mutants with a particular genotype of interest [267]. Mutations are also induced by using two or more mutagens or one repeatedly [220]. Mutagenesis of endophytic fungi leads to regulatory gene alterations, causing phenotypic changes and enhanced secondary metabolite production, although the process needs to be defined [268]. A key example by Kai et al. [269] discussed the mutagenesis of endophytes and the selection of hygromycin-resistant strains for enhanced taxol production. In endophytic fungi, mutagenesis is attempted by employing mycelia, spores, or protoplasts and applied to taxol-producing endophytes with remarkable success [242]. Although mutagenesis offers a prospective approach, mutation of endophyte mycelium highlights the demerits of genetic divergence in the offspring, and the optimization of conditions for endophyte spore mutagenesis is difficult, suggesting that protoplast fusion is the best way to induce mutagenesis [269]. Studies on mutagenesis of endophytes for strain improvement/yield enhancement focused on optimal conditions for protoplast preparation, optimizing factors such as time, pH, temperature, enzymes, medium, and culture conditions [270,271,272]. A few reports have discussed the yield enhancement of the targeted metabolite via protoplast mutagenesis [269,273] highlighting its beneficial outcomes. Zhao et al. [271] reported the generation of an improved taxol-producing strain (HDF-68) through the fusion of two mutant protoplasts of Nodulisporium sylviforme. The taxol production in the mutant strain increased to 468.62 μg/L compared to the parent endophyte strains, suggesting mutagenesis as a powerful approach for yield enhancement, with some considerations.

17. Co-Culture of Different Endophyte Strains

With the discovery of many endophytes and bio-prospection of their respective strains, the compatibility of endophytes to produce a target metabolite has been explored [153]. The individual endophyte strains are maintained or preserved as monocultures and cultured to produce high-value metabolites; however, the standard culture may not hold the potential to activate the expression of BCGs in endophytic fungi, leading to a decrease in the discovery of novel metabolites. Sequencing of whole genomes showed that multiple genes encoding bacterial/fungal enzymes surpassed the secondary metabolites in these microbes [274]. Moreover, the metabolic processes in microbes are significantly changed with little fluctuation in culture conditions, specifically in endophytes with host-balanced interactions and multipartite interactions [242]. The co-cultivation of different endophytic strains aims to activate some silent BGCs in the presence of compatible microbes and enhances the production of targeted metabolites of interest. This is relevant in the case of antibiotic production when competition governs the biosynthesis of a product in cultures [157]. Corynespora cassiicola SUK2 and Colletotrichum fructicola SUK1 (endophytic fungi), isolated from Nothapodytes nimmoniana (Grah.) Mabb. (Ghanera), demonstrated host-independent biosynthesis of CPT under fermentation conditions, with a significantly higher yield (>1.4-fold) than that of monocultures [275]. Ahamed and Ahring [257] co-cultivated E. coli with Gliocadium roseum (endophytic fungi) and increased hydrocarbon production by 100-fold, compared to pure cultures of G. roseum. Other key examples, namely co-cultivation of Phomopsis and Alternaria, led to an eightfold increase in taxol production [224], and Alternaria and Paraconiothyrium SSM001 co-cultures led to a threefold increase in taxol production, and other examples suggest that co-culturing of compatible endophyte strains highlights an attractive alternative for yield enhancement of high-value metabolites.

18. Optimization of Culture Conditions

Although the production of diverse chemical entities by endophytic fungi is prospective in addressing natural product-mediated drug discovery, the multiple factors that govern production remain poorly understood. The cultural factors that play a key role in metabolite production include temperature, pH, cultivation time, nutrients, and aeration in the medium [276]. The term OSMAC was coined by Bode et al. [277] to show that a single microbial strain may biosynthesize multiple compounds by changing culture conditions, leading to the discovery of high-value metabolites [104]. Optimization can be achieved by considering a one-factor change or multiple-factor variations for fermentation and medium optimization. In addition, the statistical design provides reliable information for experiments by enabling the analysis of experimental variables and making an accurate prediction [278]. Wang et al. [279] discussed the importance of optimization of factors (such as carbon source, pH, and temperature) for Neurospora intermedia DP8-1 (diuron-degrading endophyte) from sugarcane and reported effective biodegradation of up to 99% of the diuron present. In the endophytic fungi F. solani from Ferocactus latispinus, the pH value and nitrogen/carbon ratio were found to affect polyketide production and were optimized, resulting in a higher yield (476 μmol/L) [280]. In addition, a bioreactor was developed to monitor the consistent production of metabolites [281]. The colonization of plant internal tissues by fungal endophytes (dark condition) showed that light treatment decreased taxol production in Paraconiothyrium SSM001 and decreased the level of gene expression [282].

19. Epigenetic Modifiers

The BCGs in fungi are present in the heterochromatin state and are controlled by epigenetic processes, including DNA methylation and histone deacetylation [283]. Gene expression/silencing in fungi is regulated by chromatin modification via DNA methylation/histone deacetylation. Epigenetic modifiers such as histone deacetylase (HDAC) inhibitors have the potential to initiate remodeling of chromatin to activate BGCs [284]. In addition, 5-aza-20-deoxycytidine and 5-azacytidine (DNA methyltransferase) inhibitors are another important class of epigenetic modifiers used for the discovery of natural products. However, an in-depth understanding of secondary metabolite biosynthesis and regulation is essential for the development of new techniques for the isolation of secondary metabolites from fungi [242]. Prospective approaches for discovery/isolation of high-value metabolites include BCG-specific transcription factor overexpression, promoter exchange, or employing inducible promoters for gene activation, and applied to endophytic fungi to alter secondary metabolite networks.

20. Translational Success and Outcome of Endophyte Research

The discovery and commercial production of taxol was a landmark in endophyte biology and research and marked the bio-prospection of endophytes in natural product-mediated drug discovery. The key pharmacological metabolites, including CPT, podophyllotoxin, huperzine A, and vinca alkaloids (vincristine/vinblastine), define a novel paradigm in pharmacology, with a new hope to discover and employ high-value metabolites in therapeutic endeavors. Although endophytes continue to gain popularity as an attractive production platform for pharmaceutical therapeutics at an affordable scale, the existing and emerging bottlenecks regarding the purity of endophyte strains, sub-culturing concerns, low yields, and adverse effects need to be further addressed for maximal utilization. Recent advances in scientific interventions and high-throughput methods have made substantial contributions to endophyte research, aiming to address the projected challenges. Genetic engineering of endophytes comprising gene overexpression and gene constructs, strain mutagenesis, and co-cultivation of compatible strains is targeted toward the improvement of different endophyte strains and high yield of targeted metabolites. With the depletion of natural resources and limited availability of natural products, the bio-prospection of endophytes and their genetic improvement is an important area of research in drug discovery programs.